Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known a… Read more
Cassava Sciences Inc (SAVA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.076x
Based on the latest financial reports, Cassava Sciences Inc (SAVA) has a cash flow conversion efficiency ratio of -0.076x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.22 Million) by net assets ($81.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cassava Sciences Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Cassava Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cassava Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cassava Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Manitex International Inc
NASDAQ:MNTX
|
0.003x |
|
Knowmerce
KQ:473980
|
0.045x |
|
Xpro India Limited
NSE:XPROINDIA
|
0.021x |
|
UNIMECH
NSE:UNIMECH
|
N/A |
|
Univacco Technology
TWO:3303
|
-0.031x |
|
Compagnie des Tramways de Rouen
PA:MLTRA
|
N/A |
|
EVA Precision Industrial Holdings Limited
F:GZT
|
0.015x |
|
KlaraBo Sverige AB Series B
ST:KLARA-B
|
0.010x |
Annual Cash Flow Conversion Efficiency for Cassava Sciences Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Cassava Sciences Inc from 1999 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $145.70 Million | $-116.93 Million | -0.803x | -34.49% |
| 2023-12-31 | $137.47 Million | $-82.03 Million | -0.597x | -75.15% |
| 2022-12-31 | $227.54 Million | $-77.51 Million | -0.341x | -186.46% |
| 2021-12-31 | $253.91 Million | $-30.20 Million | -0.119x | -103.73% |
| 2020-12-31 | $92.20 Million | $-5.38 Million | -0.058x | +48.69% |
| 2019-12-31 | $22.10 Million | $-2.51 Million | -0.114x | +53.19% |
| 2018-12-31 | $19.63 Million | $-4.77 Million | -0.243x | +71.38% |
| 2017-12-31 | $9.70 Million | $-8.24 Million | -0.849x | -29.37% |
| 2016-12-31 | $18.64 Million | $-12.23 Million | -0.656x | -112.94% |
| 2015-12-31 | $29.37 Million | $-9.05 Million | -0.308x | -29.31% |
| 2014-12-31 | $40.06 Million | $-9.55 Million | -0.238x | -65.75% |
| 2013-12-31 | $48.30 Million | $-6.95 Million | -0.144x | +73.65% |
| 2012-12-31 | $13.14 Million | $-7.17 Million | -0.546x | -9220.90% |
| 2011-12-31 | $44.39 Million | $-260.00K | -0.006x | -34.88% |
| 2010-12-31 | $32.93 Million | $-143.00K | -0.004x | +96.80% |
| 2009-12-31 | $108.25 Million | $-14.69 Million | -0.136x | -226.78% |
| 2008-12-31 | $104.29 Million | $11.16 Million | 0.107x | +398.57% |
| 2007-12-31 | $103.91 Million | $2.23 Million | 0.021x | +114.14% |
| 2006-12-31 | $77.92 Million | $-11.83 Million | -0.152x | -108.49% |
| 2005-12-31 | $63.36 Million | $113.23 Million | 1.787x | +612.48% |
| 2004-12-31 | $93.40 Million | $-32.57 Million | -0.349x | -30.19% |
| 2003-12-31 | $76.56 Million | $-20.51 Million | -0.268x | +13.20% |
| 2002-12-31 | $50.22 Million | $-15.50 Million | -0.309x | -63.67% |
| 2001-12-31 | $65.62 Million | $-12.37 Million | -0.189x | -100.90% |
| 2000-12-31 | $78.69 Million | $-7.39 Million | -0.094x | +68.16% |
| 1999-12-31 | $9.14 Million | $-2.69 Million | -0.295x | -- |